tris edta buffer  (Agilent technologies)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Name:
    Buffer Advisor Software
    Description:
    Buffer Advisor software is an independent utility software to simplify ion exchange chromatography workflows and to support design of experiments DoE Buffer Advisor software provides a fast and easy way to create pH and salt gradients It eliminates the tedious and error prone method development steps of buffer preparation buffer blending and pH scouting thus significantly reducing the time required for buffer preparation
    Catalog Number:
    BUFFER-ADVISOR-SOFTWARE
    Price:
    None
    Category:
    Products Liquid Chromatography Hplc Ce Software Application Specific Software Buffer Advisor Software
    Buy from Supplier


    Structured Review

    Agilent technologies tris edta buffer
    Buffer Advisor software is an independent utility software to simplify ion exchange chromatography workflows and to support design of experiments DoE Buffer Advisor software provides a fast and easy way to create pH and salt gradients It eliminates the tedious and error prone method development steps of buffer preparation buffer blending and pH scouting thus significantly reducing the time required for buffer preparation
    https://www.bioz.com/result/tris edta buffer/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tris edta buffer - by Bioz Stars, 2021-04
    86/100 stars

    Images

    Related Articles

    Software:

    Article Title: Serum Amyloid A Receptor Blockade and Incorporation into High-Density Lipoprotein Modulates Its Pro-Inflammatory and Pro-Thrombotic Activities on Vascular Endothelial Cells
    Article Snippet: Aliquots (50 μL) of the purified lipoprotein were removed and denatured with 150 μL of 8 M guanidine hydrochloride on ice, and subsequently analysed by high performance liquid chromatography (HPLC) using a 5-μm, 25 × 0.46 cm C18 protein and peptide column (Vydac, Hesperia, CA, USA) with a 300-Å pore size. .. Apolipoproteins were eluted with a gradient of Buffer A (0.1% v /v trifluoroacetic acid) and Buffer B (90% v /v acetonitrile/H2 O) at 1 mL/min at 20 °C using an Agilent 1100 series pump (Santa Clara, CA, USA) and detected using UV absorbance (214 nm) as described previously [ ] with the following modifications: The gradient was formed starting with 75% Buffer A and 25% buffer B and the content of acetonitrile was increased linearly to 55% over 25 min, then to 90% over a further 5 min. Eluting peaks were quantified using Standard Agilent software (ChemStation v B.03.01, Agilent Technologies, Sydney, Australia) by peak area comparison and expressed as a percentage of the maximal peak area for a given condition. .. Statistics Statistical analyses were performed using GraphPad Prism statistical software v5.0 (GraphPad, CA, USA).

    Incubation:

    Article Title: Human Embryonic Gastric Xenografts in Nude Mice: a New Model of Helicobacter pylori Infection
    Article Snippet: Slides were rinsed in buffer A and then treated with a biotinylated anti-rabbit antibody (Dako) diluted 1/150 (vol/vol) in buffer A for 30 min at room temperature. .. The sections were then washed in buffer A, and endogenous peroxidase activities were blocked by incubation for 10 min in a hydrogen peroxide solution (peroxidase-blocking solution; Dako). .. Thereafter, a streptavidin-horseradish peroxidase complex (Dako) diluted 1/150 (vol/vol) in buffer A was applied to all slides for 30 min at room temperature.

    Liquid Chromatography with Mass Spectroscopy:

    Article Title: Characterization and Recombinant Expression of Terebrid Venom Peptide from Terebra guttata
    Article Snippet: RP-HPLC Purification and Mass Spectrometry Cleaved Tgu6.1 was purified by RP-HPLC (Agilent, Santa Clara, CA, USA) using an X-Bridge C18 semi-preparative column (10 × 150 mm, 5-µm particle size, Waters Corporation, Milford, MA, USA) pre-equilibrated with 95% Buffer A (0.1% TFA). .. Elution was carried out at 5 mL/min over a linear gradient of Buffer B (80% acetonitrile 0.1% TFA) from 5% to 75% in 30 min. ESI-mass spectra were recorded on an Agilent Technologies 6520 Accurate-Mass Q-TOF LC/MS. .. Samples were delivered to the mass spectrometer through chromatographic separation on the Agilent HPLC 1290, and monoisotopic average masses of peptides were calculated from sequence information using the UCSF ProteinProspector MS-Product tool ([ ], San Francisco, CA, USA).

    Article Title: Hydrophobicity of Lipid-Conjugated siRNAs Predicts Productive Loading to Small Extracellular Vesicles
    Article Snippet: The supernatants were removed, and the lipid-conjugated sense strands were purified and desalted as described previously. .. The identity of oligonucleotides was established by LC-MS analysis on an Agilent 6530 accurate-mass Q-TOF LC/MS (Agilent, Santa Clara, CA) using the following conditions: buffer A (9 mM triethylamine/100 mM hexafluoroisopropanol in water); buffer B (9 mM triethylamine/100 mM hexafluoroisopropanol in MeOH); column: Agilent AdvanceBio oligonucleotides 2.1 × 50 mm (Agilent, Santa Clara, CA); gradient for sense strand: 0–2 min (1% B–40% B) and 2–10.5 min (40% B–100% B); and gradient for the antisense strand: 0–2 min (1% B–12% B), 2–10.5 min (12% B–30% B), and 10.5–11 min (30% B–100% B). .. Sample LC-MS chromatograms of both sense strand and antisense strand are shown in .

    Flow Cytometry:

    Article Title: Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites
    Article Snippet: .. Buffer A (1 M ammonium acetate, 10% acetonitrile, pH 5.16), buffer B (90% methanol, 10% acetonitrile), flow rate (1 mL × min−1 ), injection volume (40 μL), column temperature (30°C), sample tray temperature (30°C), column (Agilent Eclipse Plus C-18, 1.8 μm, 4.6 × 75 mm, 600 bar), fluorescence photon multiplier tube (18), excitation (401 nm), and emission (627 nm), buffer running conditions: column was equilibrated with buffer A for 1 hour, 0 to 3 minutes (100% A to 65% A: 35% B), 3 to 9 minutes (65% A: 35% B to 10% A: 90% B), 9 to 14 minutes isocratic (10% A: 90% B). ..

    Injection:

    Article Title: Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites
    Article Snippet: .. Buffer A (1 M ammonium acetate, 10% acetonitrile, pH 5.16), buffer B (90% methanol, 10% acetonitrile), flow rate (1 mL × min−1 ), injection volume (40 μL), column temperature (30°C), sample tray temperature (30°C), column (Agilent Eclipse Plus C-18, 1.8 μm, 4.6 × 75 mm, 600 bar), fluorescence photon multiplier tube (18), excitation (401 nm), and emission (627 nm), buffer running conditions: column was equilibrated with buffer A for 1 hour, 0 to 3 minutes (100% A to 65% A: 35% B), 3 to 9 minutes (65% A: 35% B to 10% A: 90% B), 9 to 14 minutes isocratic (10% A: 90% B). ..

    Fluorescence:

    Article Title: Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites
    Article Snippet: .. Buffer A (1 M ammonium acetate, 10% acetonitrile, pH 5.16), buffer B (90% methanol, 10% acetonitrile), flow rate (1 mL × min−1 ), injection volume (40 μL), column temperature (30°C), sample tray temperature (30°C), column (Agilent Eclipse Plus C-18, 1.8 μm, 4.6 × 75 mm, 600 bar), fluorescence photon multiplier tube (18), excitation (401 nm), and emission (627 nm), buffer running conditions: column was equilibrated with buffer A for 1 hour, 0 to 3 minutes (100% A to 65% A: 35% B), 3 to 9 minutes (65% A: 35% B to 10% A: 90% B), 9 to 14 minutes isocratic (10% A: 90% B). ..

    Centrifugation:

    Article Title: Identification of a Novel O-Conotoxin Reveals an Unusual and Potent Inhibitor of the Human α9α10 Nicotinic Acetylcholine Receptor
    Article Snippet: .. After centrifugation, the supernatant was applied on a ZORBAX C18 semi-preparative column (9.4 × 250 mm, Agilent, Santa Clara, CA, USA) and eluted with a gradient of buffer B (0.1% TFA in 100% acetonitrile) using an Agilent 1100 HPLC system. .. Further purification was performed on a ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa Clara, CA, USA).

    High Performance Liquid Chromatography:

    Article Title: Identification of a Novel O-Conotoxin Reveals an Unusual and Potent Inhibitor of the Human α9α10 Nicotinic Acetylcholine Receptor
    Article Snippet: .. After centrifugation, the supernatant was applied on a ZORBAX C18 semi-preparative column (9.4 × 250 mm, Agilent, Santa Clara, CA, USA) and eluted with a gradient of buffer B (0.1% TFA in 100% acetonitrile) using an Agilent 1100 HPLC system. .. Further purification was performed on a ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa Clara, CA, USA).

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    Agilent technologies tris edta solution
    Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section, resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with <t>TRIS/EDTA</t> pH 9 at 95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor 647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining
    Tris Edta Solution, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/tris edta solution/product/Agilent technologies
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    tris edta solution - by Bioz Stars, 2021-04
    97/100 stars
      Buy from Supplier

    99
    Agilent technologies anti cps1
    Combining the immunoreactive scores of CAD and <t>CPS1</t> improves prognostic prediction and is particularly predictive in early stage HCC without vascular invasion. ( a ) Kaplan–Meyer plot showing overall survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( b ) Kaplan–Meyer plot showing recurrence-free survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( c ) Analysis of overall survival in relation to BCLC stage (BCLC A, low: n = 76, high = 21; BCLC B, low: n = 216, high n = 122; BCLC C, low: n = 36, high n = 25, BCLC D, low: n = 31, high: n = 3). ( d ) Analysis of overall survival in relation to macrovascular invasion detected by preoperative imaging (upper two panels, no vascular invasion, low: n = 322, high: n = 144; with vascular invasion, low: n = 37, high: n = 27) and micro- and macrovascular invasion detected during pathologic work-up (lower three panels, V0, low = 259, high: n = 83; V1, low = 53, high = 56; V2, low: n = 47, high: n = 32). ( e ) Overall survival in relation to AFP serum level (AFP
    Anti Cps1, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cps1/product/Agilent technologies
    Average 99 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cps1 - by Bioz Stars, 2021-04
    99/100 stars
      Buy from Supplier

    86
    Agilent technologies te buffer
    Combining the immunoreactive scores of CAD and <t>CPS1</t> improves prognostic prediction and is particularly predictive in early stage HCC without vascular invasion. ( a ) Kaplan–Meyer plot showing overall survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( b ) Kaplan–Meyer plot showing recurrence-free survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( c ) Analysis of overall survival in relation to BCLC stage (BCLC A, low: n = 76, high = 21; BCLC B, low: n = 216, high n = 122; BCLC C, low: n = 36, high n = 25, BCLC D, low: n = 31, high: n = 3). ( d ) Analysis of overall survival in relation to macrovascular invasion detected by preoperative imaging (upper two panels, no vascular invasion, low: n = 322, high: n = 144; with vascular invasion, low: n = 37, high: n = 27) and micro- and macrovascular invasion detected during pathologic work-up (lower three panels, V0, low = 259, high: n = 83; V1, low = 53, high = 56; V2, low: n = 47, high: n = 32). ( e ) Overall survival in relation to AFP serum level (AFP
    Te Buffer, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/te buffer/product/Agilent technologies
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    te buffer - by Bioz Stars, 2021-04
    86/100 stars
      Buy from Supplier

    Image Search Results


    Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section, resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with TRIS/EDTA pH 9 at 95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor 647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining

    Journal: Diagnostic Pathology

    Article Title: Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma

    doi: 10.1186/s13000-018-0757-1

    Figure Lengend Snippet: Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section, resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with TRIS/EDTA pH 9 at 95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor 647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining

    Article Snippet: Tissue slide pre-processing for MTP-IF Two μm thick FFPE tumor whole sections were mounted on glass slides and manually (OFF-chip) de-paraffinized by heating at 65 °C for 10 min followed by 10 min incubation with dewaxing solution (Histoclear, National Diagnostic); after being rehydrated with decreasing concentrations of ethanol (100, 95, 70 and 40% v /v, Fischer Chemical) down to tap water, slides underwent heat-induced antigen retrieval step in TRIS/EDTA solution pH 9 (Dako) at 95 °C for 30 min.

    Techniques: Chromatin Immunoprecipitation, Incubation, Staining, Blocking Assay

    Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section, resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with TRIS/EDTA pH 9 at 95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor 647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining

    Journal: Diagnostic Pathology

    Article Title: Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma

    doi: 10.1186/s13000-018-0757-1

    Figure Lengend Snippet: Working principle of the microfluidic tissue processor (MTP) and detailed time protocols. a-b The MTP device is based on a pressure-driven system, which controls the delivery of the reagents from reservoirs of either 1.5 or 50 mL. Reagents are driven to the tissue slide by passing through the reagent delivery chip (RDC) and the microfluidic tissue processor chip (MTP). The MTP chip is placed on top of the tissue section, resulting in the formation of a thin closed reaction chamber. This allows for confined epitope-antibody interaction. The exchange of reagents is done in a timeframe of 1 s, following the principle of the fast-fluidic exchange technology (FFEX). Thereafter, reagents are delivered into the waste. The clamping of the slide and the protocols details are defined via a user interface connected to the system. c The tissue slide pre-processing was performed manually (OFF chip) and included (i) dewaxing for 10 min at 65 °C followed by 10 min incubation with dewaxing solution, (ii) rehydration with decreasing concentrations of ethanol down to tap water, (iii) heat-induced antigen retrieval with TRIS/EDTA pH 9 at 95 °C for 30 min and (iv) cool-down for 20 min. The direct ALK IF staining was performed on the microfluidic device (ON chip) by using the primary antibody mouse anti-human ALK (Novocastra, clone 5A4) and a fluorescently-labelled secondary anti-mouse IgG antibody (Alexa Fluor 647). The blocking solution was 2.5% horse serum. DAPI was included in the mounting solution for counterstaining

    Article Snippet: Two μm thick FFPE tumor whole sections were mounted on glass slides and manually (OFF-chip) de-paraffinized by heating at 65 °C for 10 min followed by 10 min incubation with dewaxing solution (Histoclear, National Diagnostic); after being rehydrated with decreasing concentrations of ethanol (100, 95, 70 and 40% v /v, Fischer Chemical) down to tap water, slides underwent heat-induced antigen retrieval step in TRIS/EDTA solution pH 9 (Dako) at 95 °C for 30 min.

    Techniques: Chromatin Immunoprecipitation, Incubation, Staining, Blocking Assay

    Combining the immunoreactive scores of CAD and CPS1 improves prognostic prediction and is particularly predictive in early stage HCC without vascular invasion. ( a ) Kaplan–Meyer plot showing overall survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( b ) Kaplan–Meyer plot showing recurrence-free survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( c ) Analysis of overall survival in relation to BCLC stage (BCLC A, low: n = 76, high = 21; BCLC B, low: n = 216, high n = 122; BCLC C, low: n = 36, high n = 25, BCLC D, low: n = 31, high: n = 3). ( d ) Analysis of overall survival in relation to macrovascular invasion detected by preoperative imaging (upper two panels, no vascular invasion, low: n = 322, high: n = 144; with vascular invasion, low: n = 37, high: n = 27) and micro- and macrovascular invasion detected during pathologic work-up (lower three panels, V0, low = 259, high: n = 83; V1, low = 53, high = 56; V2, low: n = 47, high: n = 32). ( e ) Overall survival in relation to AFP serum level (AFP

    Journal: Cancers

    Article Title: Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma

    doi: 10.3390/cancers13040744

    Figure Lengend Snippet: Combining the immunoreactive scores of CAD and CPS1 improves prognostic prediction and is particularly predictive in early stage HCC without vascular invasion. ( a ) Kaplan–Meyer plot showing overall survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( b ) Kaplan–Meyer plot showing recurrence-free survival rates in patients with respect to a high or low combined CAD-CPS1 score. ( c ) Analysis of overall survival in relation to BCLC stage (BCLC A, low: n = 76, high = 21; BCLC B, low: n = 216, high n = 122; BCLC C, low: n = 36, high n = 25, BCLC D, low: n = 31, high: n = 3). ( d ) Analysis of overall survival in relation to macrovascular invasion detected by preoperative imaging (upper two panels, no vascular invasion, low: n = 322, high: n = 144; with vascular invasion, low: n = 37, high: n = 27) and micro- and macrovascular invasion detected during pathologic work-up (lower three panels, V0, low = 259, high: n = 83; V1, low = 53, high = 56; V2, low: n = 47, high: n = 32). ( e ) Overall survival in relation to AFP serum level (AFP

    Article Snippet: Anti-CPS1 (HepPar1, Dako, #IR624, mouse monoclonal, ready to use, Tris/EDTA buffer, pH 9)

    Techniques: Imaging

    Comparison of CPS1 expression with clinicopathological and molecular parameters. ( a ) Quantification of CPS1 expression detected by immunohistochemistry with respect to vascular invasion (left panel, V0: n = 347, V1: n = 109, V2: n = 80) and tumor grade (right panel, G1: n = 100, G2: n = 266, G3: n = 115). ( b ) Quantification of CPS1 expression in relation to absence or presence of the VETC pattern (VETC-: n = 440, VETC+: n = 95). ( c ) Quantification of CPS1 expression according to morphological tumor subtype (patient numbers: trabecular: 419, scirrhous: 5, pseudogl.: 18, macrotrab.: 40, steatohep.: 22, fibrolam.: 3, clear cell: 7, lymphocyte-rich: 4, HCC-CCC: 9. ( d ) CPS1 expression levels in relation to absence or presence of GS overexpression as a marker for CTNNB1 mutations/activated WNT signaling (GS neg.: n = 423, pos: n = 110). ( e ) Quantification of CPS1 mRNA in the TCGA cohort with respect to mutational status to CTNNB1 (left panel, wild type: n = 264, mutated: n = 96) and TP53 (right panel, wildtype: n = 249, mutated 111). ( f ) Quantitative analysis of CPS1 expression in tumor tissue (left panel, no cirrhosis: n = 193, cirrhosis: n = 343) and in the surrounding liver tissue (right panel, no cirrhosis: n = 187, cirrhosis: n = 346) with respect to absence of presence of liver cirrhosis). For all analyses * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.

    Journal: Cancers

    Article Title: Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma

    doi: 10.3390/cancers13040744

    Figure Lengend Snippet: Comparison of CPS1 expression with clinicopathological and molecular parameters. ( a ) Quantification of CPS1 expression detected by immunohistochemistry with respect to vascular invasion (left panel, V0: n = 347, V1: n = 109, V2: n = 80) and tumor grade (right panel, G1: n = 100, G2: n = 266, G3: n = 115). ( b ) Quantification of CPS1 expression in relation to absence or presence of the VETC pattern (VETC-: n = 440, VETC+: n = 95). ( c ) Quantification of CPS1 expression according to morphological tumor subtype (patient numbers: trabecular: 419, scirrhous: 5, pseudogl.: 18, macrotrab.: 40, steatohep.: 22, fibrolam.: 3, clear cell: 7, lymphocyte-rich: 4, HCC-CCC: 9. ( d ) CPS1 expression levels in relation to absence or presence of GS overexpression as a marker for CTNNB1 mutations/activated WNT signaling (GS neg.: n = 423, pos: n = 110). ( e ) Quantification of CPS1 mRNA in the TCGA cohort with respect to mutational status to CTNNB1 (left panel, wild type: n = 264, mutated: n = 96) and TP53 (right panel, wildtype: n = 249, mutated 111). ( f ) Quantitative analysis of CPS1 expression in tumor tissue (left panel, no cirrhosis: n = 193, cirrhosis: n = 343) and in the surrounding liver tissue (right panel, no cirrhosis: n = 187, cirrhosis: n = 346) with respect to absence of presence of liver cirrhosis). For all analyses * denotes p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.

    Article Snippet: Anti-CPS1 (HepPar1, Dako, #IR624, mouse monoclonal, ready to use, Tris/EDTA buffer, pH 9)

    Techniques: Expressing, Immunohistochemistry, Countercurrent Chromatography, Over Expression, Marker

    CPS1 is downregulated in primary hepatocellular carcinoma, further reduced during cancer progression, and predicts prognosis. ( a ) Representative images of immunohistochemical staining of HCCs with different expression levels of CPS1. The percentage of tumors with the indicated expression level are shown. Scale bar: 50 µm. ( b ) Decreased expression of CPS1 during tumor progression. Immunostainings for CPS1 of surrounding liver tissue, primary and relapse HCC, and lymph node metastasis of one individual patient. Scale bar: 50 µm. ( c ) Quantitative analysis of CPS1 expression in primary HCC compared to non-neoplastic surrounding liver tissue (left panel, surrounding liver: n = 533, HCC: n = 536) and in recurrent HCC compared to primary HCC (right panel, n = 38). ( d ) Quantification of CPS1 expression in primary HCC compared to lymph node metastasis (left panel, n = 11) and distant metastasis (right panel, n = 27). ( e ) Kaplan–Meyer plot displaying overall survival with respect to high and low CPS1 expression as detected by immunohistochemistry (HR 1.45 for low CPS1 expression, 95% confidence interval 1.15–1.84, p = 0.0019). ( f ) Analysis of overall survival with respect to high and low expression of CPS1 mRNA in the TCGA cohort (HR 2.19, 95% confidence interval 1.48–3.26, p ≤ 0.0001). For all analyses * denotes p ≤ 0.05, *** p ≤ 0.001.

    Journal: Cancers

    Article Title: Key Enzymes in Pyrimidine Synthesis, CAD and CPS1, Predict Prognosis in Hepatocellular Carcinoma

    doi: 10.3390/cancers13040744

    Figure Lengend Snippet: CPS1 is downregulated in primary hepatocellular carcinoma, further reduced during cancer progression, and predicts prognosis. ( a ) Representative images of immunohistochemical staining of HCCs with different expression levels of CPS1. The percentage of tumors with the indicated expression level are shown. Scale bar: 50 µm. ( b ) Decreased expression of CPS1 during tumor progression. Immunostainings for CPS1 of surrounding liver tissue, primary and relapse HCC, and lymph node metastasis of one individual patient. Scale bar: 50 µm. ( c ) Quantitative analysis of CPS1 expression in primary HCC compared to non-neoplastic surrounding liver tissue (left panel, surrounding liver: n = 533, HCC: n = 536) and in recurrent HCC compared to primary HCC (right panel, n = 38). ( d ) Quantification of CPS1 expression in primary HCC compared to lymph node metastasis (left panel, n = 11) and distant metastasis (right panel, n = 27). ( e ) Kaplan–Meyer plot displaying overall survival with respect to high and low CPS1 expression as detected by immunohistochemistry (HR 1.45 for low CPS1 expression, 95% confidence interval 1.15–1.84, p = 0.0019). ( f ) Analysis of overall survival with respect to high and low expression of CPS1 mRNA in the TCGA cohort (HR 2.19, 95% confidence interval 1.48–3.26, p ≤ 0.0001). For all analyses * denotes p ≤ 0.05, *** p ≤ 0.001.

    Article Snippet: Anti-CPS1 (HepPar1, Dako, #IR624, mouse monoclonal, ready to use, Tris/EDTA buffer, pH 9)

    Techniques: Immunohistochemistry, Staining, Expressing